The Global Women’s Health Therapeutics Market is Forecast to Grow Rapidly from 2010 to 2017

Monday 20 February 2012, Amsterdam

The report provides in-depth analysis of the drivers and barriers that affect the Women’s Health market and analyzes the markets for women’s health disorders in the US, the top five markets in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, revenues, annual cost of therapy and treatment flow algorithm are forecast until 2017 for the key geographies as well as the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets. The report also includes insights into the respiratory disorders R&D product pipeline.

The Global Women’s Health Therapeutics Market is Forecast to Grow Rapidly from 2010 to 2017

In 2010, the global women’s health therapeutics market was estimated to be worth $14,530m, after a Compound Annual Growth Rate (CAGR) of 3.5% between 2002 and 2010. By 2017 the market is estimated to reach $24,671m, indicating a CAGR of 7.9% between 2010 and 2017. Owing to several factors such as the publication of the Women’s Health Initiative (WHI) study results, and a lack of effective therapeutics, the women’s health therapeutics market grew only moderately between 2002 and 2010. However, the launch of novel therapeutics in the near future is expected to satisfy the unmet need in the market. This will have a pronounced effect on positive growth in the menopause therapeutics market.

See figure: Women’s Health Therapeutics Market, Global, Revenue Forecasts, ($m), 2002 - 2017

The current women’s health therapeutics pipeline is promising, with a strong line-up of first-in-class molecules in late stages of clinical development such as Pristiq (desvenlafaxine), Aprela (bazedoxifene/conjugated estrogens), Menerba (MF101) and Elagolix (NBI-56418). In addition, the recent launch of potential blockbuster drugs such as Prolia (denosumab) for the treatment of postmenopausal osteoporosis will offset the patent expirations of several major drugs, including Fosamax (alendronate sodium), Boniva (ibandronate sodium) and Actonel (risedronate sodium). The women’s health therapeutics market is an attractive market with huge opportunities for novel entrants with high safety and efficacy profiles.

Novel Therapies are Poised to Dominate the Women’s Health Disorder Therapeutics Market

The women’s health therapeutics market is backed by a strong pipeline which is expected to drive the growth of this market. Major players such as Pfizer, Inc. and Merck & Co., Inc. have attractive pipelines with many first-in-class molecules for the treatment of the menopause, osteoporosis and endometriosis. If approved, a trend shift in the treatment pattern will be seen, particularly in the menopause and osteoporosis markets.

Amgen Inc recently launched Prolia, a first-in-class drug for the treatment of postmenopausal osteoporosis. Merck’s Odanacatib (MK-0822), a cathepsin K inhibitor, has also shown promising results in postmenopausal osteoporosis treatment. The menopause therapeutics market is presently dominated by hormone therapeutics with highly questionable safety profiles. If approved for treatment and shown to be safer, non-hormones for the treatment of menopause will strongly compete with the currently marketed drugs and will significantly alter the market dynamics, with the potential to drive the menopause market sales up to $7,567m by 2017.

Deals Worth Less than $ 1,000m Accounted for 85% of Strategic Consolidations

Strategic consolidations help a company to enter a new market or consolidate its position in the market. The majority (85%) of the merger and acquisition (M&A) deals in the women’s health therapeutics market were worth less than $1,000m. Abbott will gain full control of two drugs Tricor (fenofibrate) and Trilipix (fenofibric acid), for treating cholesterol and triglycerides.